NASDAQ:XOMAO - Nasdaq - US98419J4040 - Currency: USD
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (5/5/2025, 8:00:03 PM)
25.151
+0.15 (+0.6%)
The current stock price of XOMAO is 25.151 USD. In the past month the price increased by 0.12%. In the past year, price increased by 0.2%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.09 | 346.84B | ||
AMGN | AMGEN INC | 13.49 | 150.57B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1724.79 | 128.59B | ||
GILD | GILEAD SCIENCES INC | 13.28 | 128.00B | ||
REGN | REGENERON PHARMACEUTICALS | 13.62 | 65.17B | ||
ARGX | ARGENX SE - ADR | 345.61 | 40.09B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.58B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.40B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.30B | ||
NTRA | NATERA INC | N/A | 21.40B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.81B | ||
BIIB | BIOGEN INC | 7.7 | 17.85B |
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others.
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
2200 Powell Street, Suite 310
Emeryville CALIFORNIA US
Employees: 13
Phone: 15102047239
The current stock price of XOMAO is 25.151 USD. The price increased by 0.6% in the last trading session.
The exchange symbol of XOMA ROYALTY CORP - XOMA 8 3/8 PERP is XOMAO and it is listed on the Nasdaq exchange.
XOMAO stock is listed on the Nasdaq exchange.
10 analysts have analysed XOMAO and the average price target is 71.92 USD. This implies a price increase of 185.97% is expected in the next year compared to the current price of 25.151. Check the XOMA ROYALTY CORP - XOMA 8 3/8 PERP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a market capitalization of 300.55M USD. This makes XOMAO a Small Cap stock.
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) currently has 13 employees.
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a support level at 25.14 and a resistance level at 25.21. Check the full technical report for a detailed analysis of XOMAO support and resistance levels.
The Revenue of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is expected to grow by 15.45% in the next year. Check the estimates tab for more information on the XOMAO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a dividend yield of 8.38%. The yearly dividend amount is currently 0.47. Check the full fundamental report for a detailed analysis of XOMAO dividend history, reliability and sustainability.
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) will report earnings on 2025-05-13.
XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.06).
The outstanding short interest for XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is 0.04% of its float. Check the ownership tab for more information on the XOMAO short interest.
ChartMill assigns a technical rating of 2 / 10 to XOMAO. When comparing the yearly performance of all stocks, XOMAO turns out to be only a medium performer in the overall market: it outperformed 56.9% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to XOMAO. Both the profitability and financial health of XOMAO have multiple concerns.
Over the last trailing twelve months XOMAO reported a non-GAAP Earnings per Share(EPS) of -2.06. The EPS increased by 4.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -11.87% | ||
ROE | -32.06% | ||
Debt/Equity | 1.3 |
ChartMill assigns a Buy % Consensus number of 82% to XOMAO. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 72.39% and a revenue growth 15.45% for XOMAO